fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Advertisment

Prednisolone reduces sequelae in Bell's Palsy

Written by | 31 Jul 2012 | All Medical News

by Bruce Sylvester – Emerging uses of FDA Approved Drugs –

Patients treated  for Bell palsy with prednisolone within 72 hours achieved  significantly reduced severity of  mild to moderate palsy severity at 12 months, researchers reported in the May issue of Archives of Otolaryngology – Head & Neck Surgery.
As background, the authors note that most patients recover from Bell palsy within 6 months without treatment. However, some patients have sequelae with functional, psychosocial, and esthetic consequences.
Thomas Berg, MD, Oslo University Hospital Rikshospitalet, Oslo, Norway, and colleagues  analyzed data from a large Scandivavian randomized placebo-controlled trial.
The study enrolled 829 subjects, age 18 to 75.
The investigators evaluated facial function at 12 months using the Sunnybrook and House-Brackmann grading systems.
There were four treatment cohorts,  placebo plus placebo, prednisolone plus placebo, valacyclovir plus placebo, or prednisolone plus valacyclovir.
“Treatment with prednisolone significantly reduced mild and moderate sequelae in Bell’s palsy at 12 months,” the authors reported.
“Prednisolone did not reduce the number of patients with severe sequelae. Valacyclovir alone did not affect the severity of sequelae,” they added. “The combination of prednisolone plus valacyclovir did not reduce the number of patients with sequelae compared with prednisolone alone.”

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.